vs
Side-by-side financial comparison of Mega Matrix Inc (MPU) and NovaBay Pharmaceuticals, Inc. (NBY). Click either name above to swap in a different company.
Mega Matrix Inc is the larger business by last-quarter revenue ($6.1M vs $4.8M, roughly 1.3× NovaBay Pharmaceuticals, Inc.). NovaBay Pharmaceuticals, Inc. runs the higher net margin — -25.5% vs -177.4%, a 151.9% gap on every dollar of revenue. On growth, NovaBay Pharmaceuticals, Inc. posted the faster year-over-year revenue change (126.1% vs -40.9%).
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis
MPU vs NBY — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $6.1M | $4.8M |
| Net Profit | $-10.8M | $-1.2M |
| Gross Margin | 47.7% | 65.2% |
| Operating Margin | -156.3% | -37.2% |
| Net Margin | -177.4% | -25.5% |
| Revenue YoY | -40.9% | 126.1% |
| Net Profit YoY | -291.1% | 70.5% |
| EPS (diluted) | $-0.21 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $6.1M | — | ||
| Q2 25 | $7.1M | — | ||
| Q1 25 | $7.7M | — | ||
| Q4 24 | — | $4.8M | ||
| Q3 24 | $10.3M | $0 | ||
| Q2 24 | — | $2.4M | ||
| Q1 24 | — | $2.6M | ||
| Q4 23 | — | $2.1M |
| Q3 25 | $-10.8M | — | ||
| Q2 25 | $-1.5M | — | ||
| Q1 25 | $-2.5M | — | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | $-2.8M | $-1.2M | ||
| Q2 24 | — | $-1.6M | ||
| Q1 24 | — | $-3.2M | ||
| Q4 23 | — | $-4.1M |
| Q3 25 | 47.7% | — | ||
| Q2 25 | 58.5% | — | ||
| Q1 25 | 55.8% | — | ||
| Q4 24 | — | 65.2% | ||
| Q3 24 | 58.5% | — | ||
| Q2 24 | — | 66.3% | ||
| Q1 24 | — | 68.2% | ||
| Q4 23 | — | 51.5% |
| Q3 25 | -156.3% | — | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -32.8% | — | ||
| Q4 24 | — | -37.2% | ||
| Q3 24 | -26.0% | — | ||
| Q2 24 | — | -67.4% | ||
| Q1 24 | — | -87.1% | ||
| Q4 23 | — | -48.0% |
| Q3 25 | -177.4% | — | ||
| Q2 25 | -20.7% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | — | -25.5% | ||
| Q3 24 | -26.8% | — | ||
| Q2 24 | — | -66.0% | ||
| Q1 24 | — | -122.2% | ||
| Q4 23 | — | -195.5% |
| Q3 25 | $-0.21 | — | ||
| Q2 25 | $-0.04 | — | ||
| Q1 25 | $-0.07 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.08 | $-1.92 | ||
| Q2 24 | — | $-1.37 | ||
| Q1 24 | — | $-29.95 | ||
| Q4 23 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $9.8M | $430.0K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $37.4M | $-129.0K |
| Total Assets | $42.7M | $3.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $9.8M | — | ||
| Q2 25 | $4.0M | — | ||
| Q1 25 | $6.8M | — | ||
| Q4 24 | — | $430.0K | ||
| Q3 24 | $9.9M | $776.0K | ||
| Q2 24 | — | $751.0K | ||
| Q1 24 | — | $1.8M | ||
| Q4 23 | — | $2.9M |
| Q3 25 | $37.4M | — | ||
| Q2 25 | $10.9M | — | ||
| Q1 25 | $11.9M | — | ||
| Q4 24 | — | $-129.0K | ||
| Q3 24 | $15.8M | $1.1M | ||
| Q2 24 | — | $-617.0K | ||
| Q1 24 | — | $160.0K | ||
| Q4 23 | — | $3.3M |
| Q3 25 | $42.7M | — | ||
| Q2 25 | $16.6M | — | ||
| Q1 25 | $17.3M | — | ||
| Q4 24 | — | $3.4M | ||
| Q3 24 | $22.4M | $3.9M | ||
| Q2 24 | — | $3.9M | ||
| Q1 24 | — | $5.4M | ||
| Q4 23 | — | $9.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.5M | $-1.7M |
| Free Cash FlowOCF − Capex | — | $-1.7M |
| FCF MarginFCF / Revenue | — | -35.4% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-3.5M | — | ||
| Q2 25 | $-1.8M | — | ||
| Q1 25 | $-2.2M | — | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | — | $-2.4M | ||
| Q2 24 | — | $-1.4M | ||
| Q1 24 | — | $-2.0M | ||
| Q4 23 | — | $-592.0K |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-2.0M | ||
| Q4 23 | — | $-595.0K |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -35.4% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -75.3% | ||
| Q4 23 | — | -28.3% |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.1% | ||
| Q4 23 | — | 0.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MPU
Segment breakdown not available.
NBY
| Other | $2.4M | 51% |
| Total Product Revenue | $2.3M | 49% |
